Physician profile
Ankur Jindal
NPI 1003014705
$6,407.07
in general payments reported to CMS, 2019-2025
40 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $393 · 2021: $404 · 2022: $1,159 · 2023: $1,212 · 2024: $1,157 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,236.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $708.25 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $545.68 | 2019-2025 | |
| Abbott Laboratories | $500.42 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $369.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $292.48 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $285.08 | 2022-2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $256.22 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $233.79 | 2021-2025 | Minimed 780g, Minimed 770g, Inceptiv |
| Astrazeneca Pharmaceuticals Lp | $219.46 | 2019-2021 | |
| Beta Bionics, INC. | $199.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $147.09 | 2022-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $126.68 | 2019-2020 | |
| Corcept Therapeutics | $120.04 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.54 | 2019-2025 | Jardiance, Synjardy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $88.24 | 2019-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $80.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $76.58 | 2019 | |
| Amryt Pharma Holdings Ltd | $65.69 | 2023 | Mycapssa |
| Shire North American Group INC | $61.44 | 2019 | |
| Ibsa Pharma INC. | $56.84 | 2019-2025 | Licart, Flector, Tirosint |
| Kyowa Kirin, INC. | $53.91 | 2023-2025 | Crysvita |
| Medtronic Minimed, INC. | $48.97 | 2019 | |
| Grt US Holding, INC. | $46.67 | 2022 | |
| Zealand Pharma US, INC. | $45.01 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $44.07 | 2021-2022 | |
| Chiesi USA, INC. | $37.35 | 2024-2025 | Mycapssa |
| Recordati_rare_diseases_inc. | $34.30 | 2021-2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $34.12 | 2024-2025 | Yorvipath |
| Eisai INC. | $34.02 | 2020 | |
| Mannkind Corporation | $32.36 | 2022-2025 | |
| Pfizer INC. | $31.24 | 2023-2025 | |
| Madrigal Pharmaceuticals | $28.40 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $27.92 | 2022-2024 | Unithroid |
| Senseonics, Incorporated | $23.00 | 2019-2020 | |
| Amarin Pharma, INC. | $22.80 | 2019 | |
| Amgen INC. | $21.66 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $21.12 | 2023 | |
| Intra-Sana Laboratories | $19.53 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Averitas Pharma INC. | $16.19 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.